Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Influence of additives on the properties of nanodroplets formed in highly supersaturated aqueous solutions of ritonavir.

Ilevbare GA, Liu H, Pereira J, Edgar KJ, Taylor LS.

Mol Pharm. 2013 Sep 3;10(9):3392-403. doi: 10.1021/mp400228x.

PMID:
23829687
2.

Impact of polymers on the precipitation behavior of highly supersaturated aqueous danazol solutions.

Jackson MJ, Toth SJ, Kestur US, Huang J, Qian F, Hussain MA, Simpson GJ, Taylor LS.

Mol Pharm. 2014 Sep 2;11(9):3027-38. doi: 10.1021/mp500201s.

PMID:
25105204
3.

pH-Dependent Liquid-Liquid Phase Separation of Highly Supersaturated Solutions of Weakly Basic Drugs.

Indulkar AS, Box KJ, Taylor R, Ruiz R, Taylor LS.

Mol Pharm. 2015 Jul 6;12(7):2365-77. doi: 10.1021/acs.molpharmaceut.5b00056.

PMID:
25984769
4.

Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.

Tho I, Liepold B, Rosenberg J, Maegerlein M, Brandl M, Fricker G.

Eur J Pharm Sci. 2010 Apr 16;40(1):25-32. doi: 10.1016/j.ejps.2010.02.003.

PMID:
20172027
5.

Using Environment-Sensitive Fluorescent Probes to Characterize Liquid-Liquid Phase Separation in Supersaturated Solutions of Poorly Water Soluble Compounds.

Raina SA, Alonzo DE, Zhang GG, Gao Y, Taylor LS.

Pharm Res. 2015 Nov;32(11):3660-73. doi: 10.1007/s11095-015-1725-z.

PMID:
26123681
6.

Exploiting the Phenomenon of Liquid-Liquid Phase Separation for Enhanced and Sustained Membrane Transport of a Poorly Water-Soluble Drug.

Indulkar AS, Gao Y, Raina SA, Zhang GG, Taylor LS.

Mol Pharm. 2016 Jun 6;13(6):2059-69. doi: 10.1021/acs.molpharmaceut.6b00202.

PMID:
27138900
7.

Glass-liquid phase separation in highly supersaturated aqueous solutions of telaprevir.

Mosquera-Giraldo LI, Taylor LS.

Mol Pharm. 2015 Feb 2;12(2):496-503. doi: 10.1021/mp500573z.

PMID:
25541813
8.

Characterization of Supersaturated Danazol Solutions - Impact of Polymers on Solution Properties and Phase Transitions.

Jackson MJ, Kestur US, Hussain MA, Taylor LS.

Pharm Res. 2016 May;33(5):1276-88. doi: 10.1007/s11095-016-1871-y.

PMID:
26892947
9.

Dissolution performance of binary amorphous drug combinations--Impact of a second drug on the maximum achievable supersaturation.

Trasi NS, Taylor LS.

Int J Pharm. 2015 Dec 30;496(2):282-90. doi: 10.1016/j.ijpharm.2015.10.026.

PMID:
26456250
10.

Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.

Jackson MJ, Kestur US, Hussain MA, Taylor LS.

Mol Pharm. 2016 Jan 4;13(1):223-31. doi: 10.1021/acs.molpharmaceut.5b00652.

PMID:
26618718
11.

Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.

Rumondor AC, Marsac PJ, Stanford LA, Taylor LS.

Mol Pharm. 2009 Sep-Oct;6(5):1492-505. doi: 10.1021/mp900050c.

PMID:
19634917
12.

Trends in the precipitation and crystallization behavior of supersaturated aqueous solutions of poorly water-soluble drugs assessed using synchrotron radiation.

Raina SA, Eerdenbrugh BV, Alonzo DE, Mo H, Zhang GG, Gao Y, Taylor LS.

J Pharm Sci. 2015 Jun;104(6):1981-92. doi: 10.1002/jps.24423.

PMID:
25808078
13.

Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions.

Law D, Krill SL, Schmitt EA, Fort JJ, Qiu Y, Wang W, Porter WR.

J Pharm Sci. 2001 Aug;90(8):1015-25.

PMID:
11536205
14.
15.

Phase Behavior of Resveratrol Solid Dispersions Upon Addition to Aqueous media.

Wegiel LA, Mosquera-Giraldo LI, Mauer LJ, Edgar KJ, Taylor LS.

Pharm Res. 2015 Oct;32(10):3324-37. doi: 10.1007/s11095-015-1709-z.

PMID:
25975588
16.

Sodium Lauryl Sulfate Competitively Interacts with HPMC-AS and Consequently Reduces Oral Bioavailability of Posaconazole/HPMC-AS Amorphous Solid Dispersion.

Chen Y, Wang S, Wang S, Liu C, Su C, Hageman M, Hussain M, Haskell R, Stefanski K, Qian F.

Mol Pharm. 2016 Aug 1;13(8):2787-95. doi: 10.1021/acs.molpharmaceut.6b00391.

PMID:
27337060
17.

PH-induced nanosegregation of ritonavir to lyotropic liquid crystal of higher solubility than crystalline polymorphs.

Rodríguez-Spong B, Acciacca A, Fleisher D, Rodríguez-Hornedo N.

Mol Pharm. 2008 Nov-Dec;5(6):956-67. doi: 10.1021/mp800114k.

PMID:
19434919
18.

Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs.

Raina SA, Zhang GG, Alonzo DE, Wu J, Zhu D, Catron ND, Gao Y, Taylor LS.

J Pharm Sci. 2014 Sep;103(9):2736-48. doi: 10.1002/jps.23826.

PMID:
24382592
19.

Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations.

Law D, Schmitt EA, Marsh KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y.

J Pharm Sci. 2004 Mar;93(3):563-70.

PMID:
14762895
20.

Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.

Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, Hussain M.

Pharm Res. 2012 Oct;29(10):2765-76.

PMID:
22315020
Items per page

Supplemental Content

Support Center